Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cancer|May 2, 2013
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancerPasquale F Innominato, Sylvie Giacchetti, Thierry Moreau, et al.
The Journal of Pharmacy and Pharmacology|August 16, 2017
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinomaJessica Cusato, Silvia De Francia, Sarah Allegra, et al.
Cancer|July 23, 2013
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan studyFrancesco Leone, Salvatore Artale, Donatella Marino, et al.
Cancer Research|May 28, 2009
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancerPasquale F Innominato, Christian Focan, Thierry Gorlia, et al.
Cancer Research and Treatment|November 19, 2016
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-AnalysisChiara Cremolini, Carlotta Antoniotti, Filippo Pietrantonio, et al.
The Oncologist|September 8, 2012
The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective studyMarco Tampellini, Azzurra Ottone, Elisa Bellini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy GroupSylvie Giacchetti, Georg Bjarnason, Carlo Garufi, et al.
Breast Cancer Research and Treatment|May 4, 2006
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patientsMarco Tampellini, Alfredo Berruti, Raffaella Bitossi, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
British Journal of Cancer|May 20, 2020
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, et al.
Pageof 5